Featured Research

from universities, journals, and other organizations

No Test Needed For Hand-foot Genital Syndrome In Women Without HOXA13 Gene Mutation, Study Finds

Date:
October 19, 2009
Source:
Yale University
Summary:
Researchers have found that women without mutations of the HOXA13 gene do not need to be subjected to X-rays and other tests for a rare condition called hand-foot genital syndrome.

Hugh S. Taylor, M.D., professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at Yale, and colleagues have found that women without mutations of the HOXA13 gene do not need to be subjected to x-rays and other tests for a rare condition called hand-foot genital syndrome.

The research is presented at the American Society for Reproductive Medicine (ASRM) scientific meeting in Atlanta, Georgia, October 17-21.

Hand-foot genital syndrome affects the development of the hands and feet, the urinary tract, and the reproductive system. Some women with this disorder could be at increased risk of pregnancy loss, premature labor and stillbirth. Hand-foot genital syndrome is caused by mutations in the HOXA13 gene, which is one of the genes that control the development of the uterus.

Taylor and colleagues studied women who had classic hand-foot genital syndrome and found a new mutation in the gene that had not been described before. The team then looked at women with other uterine disorders and did not find any mutations in HOXA 13. This ruled out the possibility that they could have hand-foot genital syndrome.

"This finding reduces the need for women to undergo these unnecessary and expensive tests," said Taylor.


Story Source:

The above story is based on materials provided by Yale University. Note: Materials may be edited for content and length.


Cite This Page:

Yale University. "No Test Needed For Hand-foot Genital Syndrome In Women Without HOXA13 Gene Mutation, Study Finds." ScienceDaily. ScienceDaily, 19 October 2009. <www.sciencedaily.com/releases/2009/10/091019172341.htm>.
Yale University. (2009, October 19). No Test Needed For Hand-foot Genital Syndrome In Women Without HOXA13 Gene Mutation, Study Finds. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/10/091019172341.htm
Yale University. "No Test Needed For Hand-foot Genital Syndrome In Women Without HOXA13 Gene Mutation, Study Finds." ScienceDaily. www.sciencedaily.com/releases/2009/10/091019172341.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins